Cardiff Oncology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group, Inc. has amended its Schedule 13G filing for Cardiff Oncology Inc, reporting 0% beneficial ownership due to an internal corporate realignment.
NASDAQ
Commodore Capital LP and Commodore Capital Master LP report zero beneficial ownership in Cardiff Oncology, Inc., indicating a full divestment of their previous stake.
NASDAQ
The Vanguard Group has reported a 5.6% beneficial ownership stake in Cardiff Oncology Inc., holding 3,728,334 shares of common stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Cardiff Oncology, Inc.
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Pfizer Discloses 3.6% Stake in Cardiff Oncology, Inc. via Amended Schedule 13G Filing
Pfizer Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of Cardiff Oncology, Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses Reduced Passive Stake in Cardiff Oncology, Inc. Below 5% Threshold
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.3% passive beneficial ownership stake in Cardiff Oncology, Inc. as of December 31, 2024.